Idacta mAb INT-001 represents an promising therapeutic strategy for treating certain hematologic cancers. This antibody shows the special mechanism of function, specifically targeting CD38, an exterior antigen https://dirstop.com/story28131708/idacta-mab-int-001-an-novel-antigen-binding-protein-in-development